INHIBRX

inhibrx-logo

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases and infectious diseases. Inhibrx has collaborations with Celgene and bluebird bio and has received awards from several granting agencies, including NIH, NIAID and CARB-X.

#SimilarOrganizations #People #Financial #Event #Website #More

INHIBRX

Industry:
Biotechnology Therapeutics

Founded:
2010-01-01

Address:
La Jolla, California, United States

Country:
United States

Website Url:
http://www.inhibrx.com

Total Employee:
51+

Status:
Active

Total Funding:
69.59 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics


Similar Organizations

sagimet-biosciences-logo

Sagimet Biosciences

Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.

hookipa-pharma-logo

Hookipa Pharma

Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.

scholar-rock-logo

Scholar Rock

Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.

Current Employees Featured

mark-lappe_image

Mark Lappe
Mark Lappe Co-Founder & CEO @ Inhibrx
Co-Founder & CEO

quinn-deveraux_image

Quinn Deveraux
Quinn Deveraux CSO & Co-Founder @ Inhibrx
CSO & Co-Founder
2018-01-01

not_available_image

Klaus W. Wagner
Klaus W. Wagner CMO @ Inhibrx
CMO

brendan-eckelman_image

Brendan Eckelman
Brendan Eckelman COO & Co-Founder @ Inhibrx
COO & Co-Founder

kelly-deck_image

Kelly Deck
Kelly Deck Chief Financial Officer @ Inhibrx
Chief Financial Officer

david-kao_image

David Kao
David Kao Vice President Regulatory Affairs @ Inhibrx
Vice President Regulatory Affairs
2021-01-01

jack-tsai_image

Jack Tsai
Jack Tsai VP Business Development @ Inhibrx
VP Business Development
2021-10-01

david-matly_image

David Matly
David Matly EVP Chief Commercial Officer @ Inhibrx
EVP Chief Commercial Officer
2021-10-01

Founder


brendan-eckelman_image

Brendan Eckelman

mark-lappe_image

Mark Lappe

quinn-deveraux_image

Quinn Deveraux

Stock Details


Company's stock symbol is NASDAQ:INBX

Investors List

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Convertible Note - Inhibrx

alexandria-venture_image

Alexandria Venture

Alexandria Venture investment in Convertible Note - Inhibrx

lilly-asia-ventures_image

Lilly Asia Ventures

Lilly Asia Ventures investment in Convertible Note - Inhibrx

arrowpoint-partners_image

ArrowMark Partners

ArrowMark Partners investment in Convertible Note - Inhibrx

wuxi-biologics_image

WuXi Biologics

WuXi Biologics investment in Convertible Note - Inhibrx

viking-global-investors_image

Viking Global Investors

Viking Global Investors investment in Convertible Note - Inhibrx

carb-x_image

CARB-X

CARB-X investment in Grant - Inhibrx

oxford-finance-corporation_image

Oxford Finance LLC

Oxford Finance LLC investment in Debt Financing - Inhibrx

Official Site Inspections

http://www.inhibrx.com Semrush global rank: 2.76 M Semrush visits lastest month: 5.86 K

  • Host name: 199.16.172.244
  • IP address: 199.16.172.244
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Inhibrx"

Inhibrx - Crunchbase Company Profile & Funding

Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.See details»

Investors | Inhibrx Bioscience Inc. | Adaptable

Inhibrx, inc. - Report of Organizational Actions Affecting Basis of Securities On May 29, 2024, Inhibrx, inc. (the โ€œcompanyโ€) distributed 92% of the issued and outstanding shares of the common stock in its subsidiary, Inhibrx biosciences, โ€ฆSee details»

Our Team | Inhibrx | Meet our experts in biotherapeutics.

With proven track records in biotherapeutics and a commitment to synergistic teamwork, we find that our people are as dynamic as our technology.See details»

Inhibrx - Funding, Financials, Valuation & Investors - Crunchbase

Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.See details»

Inhibrx - Contacts, Employees, Board Members, Advisors & Alumni

Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.See details»

Inhibrx, Inc. - Drug pipelines, Patents, Clinical trials - Synapse

About Inhibrx Biosciences, Inc. Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates.See details»

Inhibrx Biosciences, Inc. - LinkedIn

Inhibrx Biosciences, Inc. | 5,720 followers on LinkedIn. Innovation Focused Outcomes Driven | At Inhibrx, our mission is to deliver optimized, biologic therapeutics to people with life-threatening ...See details»

Inhibrx | Investors - Investors

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare โ€ฆSee details»

InhibRx Company Profile - Office Locations, Competitors ... - Craft

InhibRx has 5 employees at their 1 location and $1.8 m in annual revenue in FY 2023. See insights on InhibRx including office locations, competitors, revenue, financials, executives, โ€ฆSee details»

Sanofi completes acquisition of Inhibrx, Inc.

May 30, 2024 Sanofi announced today the completion of its acquisition of Inhibrx, Inc. (โ€œInhibrxโ€). The acquisition adds SAR447537 (formerly INBRX-101) to Sanofiโ€™s rare disease pipeline, โ€ฆSee details»

Inhibrx: The Biotech Spinoff Poised For Big Gains

Sep 15, 2024 Discover why Inhibrx is a hidden gem in biotech, poised for major growth with innovative treatments. For more investment insights, reach out or explore my company todaySee details»

Who We Are | Inhibrx | Fresh perspective. Validated targets.

At Inhibrx youโ€™ll not only find a cohort of established, focused, and meticulous scientists, but also a close-knit, creative, and adventurous team. With a shared vision and intrinsic motivation to get โ€ฆSee details»

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

6 days ago Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the โ€ฆSee details»

Inhibrx Biosciences - Overview, News & Similar companies

Nov 4, 2024 View Inhibrx Biosciences (www.inhibrx.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees โ€ฆSee details»

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best ...

Jan 23, 2006 Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline Acquisition supports Sanofiโ€™s portfolio growth โ€ฆSee details»

INBRX-106 | Inhibrx | Utilizing a member of the TNFRSF.

OX40 is a member of the TNFRSF (TNF receptor superfamily). We believe INBRX-106, our hexavalent OX40 agonist, can outperform bivalent agonists.See details»

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate โ€ฆ

Jan 23, 2024 Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that โ€ฆSee details»

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

6 days ago SAN DIEGO, March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and โ€ฆSee details»

Inhibrx (INBX) Earnings Date and Reports 2025 - MarketBeat

3 days ago When is Inhibrx's next earnings announcement? View the latest INBX earnings date, analysts forecasts, earnings history, and conference call transcripts.See details»

Inhibrx, Inc.

It is the policy of Inhibrx, Inc. (the โ€œCorporationโ€) that the Nominating and Corporate Governance Committee (the โ€œCommitteeโ€) of the Board of Directors (the โ€œBoardโ€) consider โ€ฆSee details»

linkstock.net © 2022. All rights reserved